EC approves Merck's Keytruda to treat melanoma

Merck & Co. Inc. (NYSE:MRK) said the EC approved an MAA for Keytruda pembrolizumab for first-line and previously treated patients with unresectable or metastatic melanoma.

FDA approved the humanized IgG4 mAb against PD-1 last year to treat advanced melanoma patients who previously received Yervoy ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY). Yervoy is a human mAb against CTLA-4 receptor. ...